Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.
Novavax, Inc. (NASDAQ: NVAX) is a biotechnology company focused on vaccines, using a platform that combines protein-based nanoparticles with its proprietary Matrix-M® adjuvant. News about Novavax often centers on its COVID-19 vaccine Nuvaxovid™/Nuvaxovid®, its broader infectious disease pipeline, and the progress of key partnerships and collaborations.
Recent announcements highlight Novavax’s collaboration and license agreement with Sanofi, under which Sanofi has taken on lead commercial and regulatory responsibilities for Nuvaxovid in selected markets. News items cover marketing authorization transfers in the European Union and United States, milestone payments to Novavax, and Sanofi’s clinical data on combination vaccine candidates that incorporate Nuvaxovid and Matrix-M. Updates also describe regulatory approvals in markets such as Japan through partner Takeda, triggering additional milestone payments and royalty opportunities.
Investors following NVAX news will see regular coverage of quarterly financial results, revenue composition from product sales, supply sales and licensing and royalty streams, as well as information on Novavax’s site consolidation and cost footprint in Maryland. The company’s communications also describe early-stage research on vaccine candidates for shingles, Clostridioides difficile colitis and respiratory syncytial virus combinations, and the use of Matrix-M in the R21/Matrix-M malaria vaccine developed with Serum Institute of India and Oxford University.
This page aggregates press releases, conference participation announcements, regulatory updates and other material events related to Novavax. Readers can use it to monitor developments in the company’s vaccine programs, partnership milestones, capital structure transactions and strategic transformation as disclosed in public statements.
Novavax (Nasdaq: NVAX) has received Fast Track Designation from the FDA for its COVID-19 vaccine candidate, NVX-CoV2373. This designation aims to expedite the development and regulatory review process, highlighting the urgent need for an effective vaccine. The Phase 3 clinical trial in the U.S. and Mexico is expected to begin by the end of November 2020, with interim data anticipated from the UK trial in early 2021. Novavax has secured $2 billion in funding for its global vaccine program.
Novavax, a late-stage biotechnology company, signed a non-binding Heads of Terms with the Australian Government to supply 40 million doses of its COVID-19 vaccine candidate, NVX-CoV2373. The arrangement aims to provide access to the vaccine, pending successful Phase 3 trials and approval by the Therapeutic Goods Administration. Initial deliveries are expected in the first half of 2021. Notably, Australia has contributed to clinical trials, enhancing the vaccine's development, while Novavax has secured $2 billion in funding for its global vaccine program.
Novavax, Inc. (NASDAQ: NVAX) has appointed Gregg Alton, J.D., as an independent Director on its Board. Alton, with over 20 years of experience, previously held various leadership roles at Gilead Sciences, including interim CEO. This addition comes at a crucial time as Novavax prepares to launch a Phase 3 trial of its COVID-19 vaccine and advance its NanoFlu vaccine toward FDA registration. Alton's extensive background in commercial operations and public affairs is expected to bolster Novavax's efforts in vaccine commercialization.
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company, will report its Q3 2020 financial and operational results on November 9, 2020, after U.S. market close. The conference call is scheduled for 4:30 p.m. ET on the same day. Interested parties can join via a domestic dial-in number (877) 212-6076 or international number (707) 287-9331, using passcode 8059421. The replay will be available from 7:30 p.m. ET on November 9 until November 16, 2020. Novavax is focused on developing vaccines for infectious diseases, including its COVID-19 vaccine candidate NVX-CoV2373.
Novavax, Inc. (Nasdaq: NVAX) has announced the expansion of its Gaithersburg campus, adding two properties to enhance its capabilities in vaccine research, manufacturing, and business operations. This move supports its ongoing COVID-19 vaccine trials and the development of its influenza vaccine, NanoFlu. The company has secured $2 billion in funding for its vaccine efforts, including $1.6 billion from the U.S. government. The new facilities will include 122,000 square feet for operations and will begin preparations for use in early 2021.
Novavax, Inc. (Nasdaq: NVAX) has enrolled over 5,500 participants in its U.K. Phase 3 clinical trial for NVX-CoV2373, aimed at assessing safety and efficacy against COVID-19. The trial will expand to 15,000 participants, with full enrollment expected by the end of November. Event-driven interim data may be available as early as Q1 2021. A U.S. Phase 3 trial is anticipated to start by the end of November, although it faced some manufacturing delays. Novavax will present new data from its ongoing Phase 1/2 trial during the CDC's ACIP meeting on October 30.
Novavax, Inc. (Nasdaq: NVAX) announced the presentation of its COVID-19 vaccine, NVX-CoV2373, at the virtual 2020 World Vaccine Congress Europe from October 19-21, 2020. Gregory M. Glenn, M.D., President of Research & Development, will discuss the recombinant nanoparticle vaccine platform. NVX-CoV2373 is engineered from the SARS-CoV-2 genetic sequence and incorporates Novavax's Matrix-M™ adjuvant to enhance immune response. The vaccine has shown promising results in preclinical trials and is in Phase 1 and Phase 3 clinical evaluations, supported by $2 billion in funding for its global vaccine program.
Novavax, Inc. (Nasdaq: NVAX) has formed a leadership team aimed at advancing its NanoFlu vaccine towards global licensure. Russell (Rip) Wilson has been promoted to Executive Vice President and NanoFlu General Manager, focusing on regulatory approvals for NanoFlu and a potential combined influenza/COVID-19 vaccine. The company intends to file a biologics licensing application (BLA) for NanoFlu, which has completed a successful Phase 3 trial. The new team includes experienced Novavax veterans to enhance development efforts across its vaccine pipeline.
Novavax (Nasdaq: NVAX) announced participation in four investor and industry conferences to discuss its COVID-19 vaccine candidate, NVX-CoV2373. Key events include the Maryland Life Sciences Bio Innovation Conference and the Guggenheim Vaccines and Infectious Diseases Conference, both on October 5, 2020. The vaccine uses proprietary recombinant nanoparticle technology and has shown promising results in clinical trials, demonstrating robust antibody responses. Novavax has secured $2 billion in funding for its global vaccine initiative, enhancing its position in addressing COVID-19.
Novavax, Inc. (Nasdaq: NVAX) announced its presentations at the 2020 World Vaccine Congress, featuring vaccines NVX-CoV2373, NanoFlu™, and ResVax™. Presenters Gregory Glenn and Vivek Shinde will discuss innovative vaccine development for COVID-19, influenza, and RSV from September 28 to October 1, 2020. Key presentation topics include the recombinant nanoparticle COVID-19 vaccine platform and new data on maternal RSV and influenza vaccines. Novavax has secured $2 billion in funding for its global coronavirus vaccine program, emphasizing its commitment to addressing urgent public health needs.